Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in September - Earnings Summary

Kiniksa Pharmaceuticals International

01/11/2021 12:40

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ  reported a quarterly
adjusted loss of 44 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 65 cents per share.
* Revenue was $12.10 million​;  analysts expected $10.18
million. 
* Kiniksa Pharmaceuticals Ltd's reported EPS for the quarter was
a loss of 44 cents​.
* The mean earnings estimate of analysts had risen by
about 10.1% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Kiniksa Pharmaceuticals Ltd shares had fallen by 8.8% this
quarter and lost 41.2% so far this year.
* The company reported a quarterly loss of $30.54 million.
* Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $30.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 1 at 12:40 p.m.
 ​All figures in US dollars unless otherwise stated